Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicitas Hitz

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Oncology|September 14, 2022
Decision-Making among Experts in Advanced Hodgkin LymphomaFelicitas Hitz, Noémie Lang, Ulrich Mey, et al.
Swiss Medical Weekly|January 29, 2025
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literatureRamona Meier-Lienhard, Cosima Suter, Thomas Pabst, et al.
BMC Cancer|June 18, 2022
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialLutz van Heek, Colin Stuka, Helen Kaul, et al.
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
Hematological Oncology|June 17, 2017
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutionsStefania Gobba, Alden A Moccia, Wiebke Gulden-Sala, et al.
Swiss Medical Weekly|July 26, 2018
Diagnosis and treatment of follicular lymphoma: an updateMario Bargetzi, Reto Baumann, Sergio Cogliatti, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|March 29, 2016
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08Felicitas Hitz, Emanuele Zucca, Thomas Pabst, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Oncology|September 14, 2022
Decision-Making among Experts in Advanced Hodgkin LymphomaFelicitas Hitz, Noémie Lang, Ulrich Mey, et al.
Swiss Medical Weekly|January 29, 2025
Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literatureRamona Meier-Lienhard, Cosima Suter, Thomas Pabst, et al.
BMC Cancer|June 18, 2022
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialLutz van Heek, Colin Stuka, Helen Kaul, et al.
Blood|February 3, 2016
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trialsBoris Böll, Helen Goergen, Karolin Behringer, et al.
Hematological Oncology|June 17, 2017
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutionsStefania Gobba, Alden A Moccia, Wiebke Gulden-Sala, et al.
Swiss Medical Weekly|July 26, 2018
Diagnosis and treatment of follicular lymphoma: an updateMario Bargetzi, Reto Baumann, Sergio Cogliatti, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|March 29, 2016
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08Felicitas Hitz, Emanuele Zucca, Thomas Pabst, et al.
Leukemia & Lymphoma|June 28, 2016
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphomaAlden A Moccia, Felicitas Hitz, Paul Hoskins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, et al.
Pageof 6